Midostaurin has been in the lab for over 10 years, still not approved for an indication. Appears to overlap with several Pona targets, FLT-3, c-KIT, VEGFR-2, PDGFR . Most current trials are combo studies with chemo in AML.
I think we will see many more Pona combos as labs around the world understand Pona just makes their drugs better. I sense a nice revenue stream flowing with little to no outlay.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.